Xenova Group’s TA-NIC for the Treatment of Nicotine Addiction
July 14, 2004 by admin · Leave a Comment
On July 14, 2004 Xenova Group plc released results of a second clinical trial with TA-NIC, a therapeutic vaccine under development for the treatment of nicotine addiction. The company reported that this randomized, placebo controlled, double-blinded study involved a total of 60 smokers and was designed to prove safety and tolerability data while measuring anti-nicotine [...]
Acomplia (rimonabant)
March 12, 2004 by admin · Leave a Comment
On March 9, 2004 Sanofi-Synthelabo announced preliminary Phase III results for Acomplia™ (rimonabant), in two clinical trials: the Stratus-US (smoking cessation) trial and the RIO-Lipids/weight loss (obesity) trial. The Stratus-US trial randomized 787 smokers who wanted to quit to use either a placebo, a 5-milligram daily dose of Acomplia or a 20-milligram daily dose, in [...]